KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $975,222 | -75.7% | 108,358 | -81.8% | 0.01% | -77.8% |
| Q4 2022 | $4,014,156 | -63.3% | 593,810 | -21.1% | 0.05% | -64.7% |
| Q3 2022 | $10,924,000 | +2.1% | 752,881 | -30.7% | 0.15% | -7.3% |
| Q2 2022 | $10,695,000 | +46.0% | 1,086,883 | +118.7% | 0.16% | +38.7% |
| Q1 2022 | $7,326,000 | +299.0% | 497,014 | +258.2% | 0.12% | +357.7% |
| Q4 2021 | $1,836,000 | -18.7% | 138,738 | +7.3% | 0.03% | -29.7% |
| Q3 2021 | $2,257,000 | -7.4% | 129,351 | +27.2% | 0.04% | -17.8% |
| Q2 2021 | $2,437,000 | -57.7% | 101,706 | -54.6% | 0.04% | -64.8% |
| Q1 2021 | $5,756,000 | – | 224,059 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |